Uncategorized

Covid-19 Update From Cycle Regarding Nityr

Covid-19 Update From Cycle Regarding Nityr At Cycle Pharmaceuticals, the health and safety of patients with tyrosinemia type 1 (HT-1) is our top priority. As the Coronavirus increases in worldwide prevalence, please have full confidence that the supply chain for NITYR® (nitisinone) Tablets is fully organized and managed to serve patients with HT-1 and their […]

Covid-19 Update From Cycle Regarding Nityr Read More »

CYCLE PHARMACEUTICALS LAUNCHES NEW INFORMATIVE ONLINE MEETING SERIES FOR PATIENTS WITH TYROSINEMIA TYPE 1 IN THE US

Cycle Pharmaceuticals Launches New Informative Online Meeting Series For Patients With Tyrosinemia Type 1 In The Us Boston (MA), USA, April 13, 2020 – Cycle Pharmaceuticals (“Cycle”) is pleased to announce the launch of a new online meeting series for patients and their families with Hereditary Tyrosinemia Type 1 (HT-1) in the US. The meeting

CYCLE PHARMACEUTICALS LAUNCHES NEW INFORMATIVE ONLINE MEETING SERIES FOR PATIENTS WITH TYROSINEMIA TYPE 1 IN THE US Read More »

A MESSAGE FROM OUR CEO AT NUTRICIA NORTH AMERICA ON COVID-19

A Message From Our Ceo At Nutricia North America On Covid-19 Dear Nutricia Customers and Community, At Nutricia, we know that our customers, patients, and their families rely on our medical foods every day. The health and safety of our customers and patients have always been our highest priority. As the COVID- 19 situation continues

A MESSAGE FROM OUR CEO AT NUTRICIA NORTH AMERICA ON COVID-19 Read More »